RxDoctor Payments DataLook up a doctor →

John Isaac, MD

Interventional Cardiology · Houston, TXNPI 1295799005

Payments from drug & device makers

$1,779,317in general payments, 2019–2025

Across 3,268 payments — averaging $544.47 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Esperion Therapeutics, Inc.$356K
  • Amgen$319K
  • AstraZeneca$215K
  • Boehringer Ingelheim$128K
  • E.r. Squibb & Sons, L.L.C.$125K
  • Sanofi-aventis U.S. LLC$118K
  • plus $518K from 52 others

What the payments were for

  • Consulting fees$72,7454%
  • Speaking & faculty fees$1,442,49881%
  • Travel & lodging$193,03811%
  • Food & beverage$70,9554%
  • Education$820%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Esperion Therapeutics, Inc.413$355,721
Amgen523$318,809
AstraZeneca284$215,189
Boehringer Ingelheim166$127,835
E.r. Squibb & Sons, L.L.C.258$125,497
Sanofi-aventis U.S. LLC150$118,009
Amarin Pharma, Inc.166$87,213
Johnson & Johnson(2 entities)177$85,251
Lilly USA, LLC106$78,502
Regeneron Healthcare Solutions, Inc.101$58,364
Kiniksa Pharmaceuticals International, PLC57$48,427
Kiniksa Pharmaceuticals, Ltd.37$27,336
Novartis145$26,955
Heartflow, Inc.48$19,999
Impulse Dynamics (USA) Inc.69$16,345
Althera Pharmaceuticals LLC10$13,751
Boston Scientific63$13,447
Pfizer86$12,252
Novo Nordisk54$10,684
Abbott154$8,550
Medicure Pharma Inc.2$5,035
Medtronic(2 entities)53$1,608
Merck32$668
Abiomed1$592
Alnylam Pharmaceuticals Inc.6$287
Actelion Pharmaceuticals US, Inc.7$287
Bayer4$262
Watermark Medical, Inc.1$224
Astellas Pharma US Inc9$198
Arbor Pharmaceuticals, Inc.12$191
BTG International Inc.2$170
Biotronik Inc.4$165
Lexicon Pharmaceuticals, Inc.5$146
Elutia, Inc.7$124
Irhythm Technologies, Inc.5$120
Acacia Pharma Inc1$117
Cardiva Medical, Inc.4$111
Bard Peripheral Vascular, Inc.5$109
ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)5$102
Inspire Medical Systems, Inc.3$90
Kowa Pharmaceuticals America, Inc.4$58
Scpharmaceuticals Inc.3$51
GSK2$46
Preventice Services, LLC2$42
G Medical Diagnostic Services, Inc.1$42
Altathera Pharmaceuticals LLC2$41
Azurity Pharmaceuticals, Inc.2$37
Smith+Nephew2$32
Avinger Inc.2$32
Chiesi USA, Inc.2$28
Tactile Systems Technology Inc2$28
Lundbeck LLC1$25
Cvrx, Inc.2$24
Agepha Pharma FZ LLC1$21
Kestra Medical Technology Services, Inc.1$19
Edwards Lifesciences1$18
Vivaquant Inc, Dba Rhythm Express2$17
Regeneron1$16

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,779,317 in reported general payments places this provider in the 95th percentile of 686 interventional cardiology providers in Texas.

See all interventional cardiology providers in Texas

Medicare billing

Part B allowed, 2024
$2,292,816
Medicare patients
1,253
Services billed
9,530

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban881$1,115,667
Repatha SureclickEvolocumab1,403$1,104,081
EntrestoSacubitril/Valsartan256$397,344
MultaqDronedarone Hcl138$263,820
XareltoRivaroxaban177$238,661
VascepaIcosapent Ethyl255$219,917
JardianceEmpagliflozin165$219,290
Praluent PenAlirocumab302$206,886
FarxigaDapagliflozin Propanediol154$176,325
NexlizetBempedoic Acid/Ezetimibe181$168,812
BrilintaTicagrelor175$147,932
OzempicSemaglutide72$71,647
Icosapent Ethyl167$69,245
Ezetimibe2,335$63,077
CorlanorIvabradine Hcl36$30,677

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$12,252$1,115,667881 claims
NovartisEntresto$26,955$397,344256 claims
AstraZenecaFarxiga, Brilinta$215,189$324,257329 claims
Sanofi-aventis U.S. LLCMultaq$118,009$263,820138 claims
Johnson & JohnsonXarelto$85,251$238,661177 claims
Boehringer IngelheimJardiance$127,835$219,290165 claims
Esperion Therapeutics, Inc.Nexlizet, Nexletol$355,721$186,159196 claims
Novo NordiskOzempic$10,684$71,64772 claims
AmgenCorlanor$318,809$30,67736 claims
Kowa Pharmaceuticals America, Inc.Livalo$58$14,45015 claims
Arbor Pharmaceuticals, Inc.Edarbi$191$7,57411 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 686 interventional cardiology providers in Texas.

Other interventional cardiology in Houston

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →